Gastric cancer remains a major health challenge worldwide, with nearly 1 million new cases annually contributing to more than ...

Thetis Pharmaceuticals LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) ...

Colorectal Cancer: Immune Reprogramming and Combination ... IBD: Barrier Protection and Mucosal Homeostasis In a second oral presentation, “TP-317, a Novel BLT1 Agonist Oral Therapy for IBD ...

Soon-Shiong said that oral vaccines could have another key advantage as they stimulate mucosal, systemic and ... immunotherapies and cell therapies for cancer and infectious diseases.

RedHill supports an independent medical education grant that includes a new two-part H. Pylori Continuing Medical Education (CME) program, develop ...

Oral squamous cell carcinoma (OSCC) is a leading cause of cancer-related deaths, and early detection is key to improving ...

Learn how HPV transmitted through oral sex can lead to throat cancer and discover the essential prevention strategies that ...

Dental infections can become much more dangerous when the immune system is weakened, as it is during chemotherapy.

Watch WXII's Jackie Pascale's full interview with oral medicine specialist Dr. Shaiba Sandhu in the video player above to hear about the life-saving treatment many cancer patients need before they ...

Radiation therapy remains the primary method of treatment for patients with head and neck cancer. The tissue destruction and functional alterations in the oral cavity lead to the development of ...

Preliminary results from the AACR 2025 Annual Meeting reveal encouraging clinical responses to the investigational oral agent ...